Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor
go back to main search page
Accession:CHEBI:88285 term browser browse the term
Definition:An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of duals specificity kinases acting on Ser/Thr and Tyr residues.
Synonyms:related_synonym: EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitors;   EC 2.7.12.* inhibitor;   EC 2.7.12.* inhibitors;   inhibitor of dual-specificity kinases (those acting on Ser/Thr and Tyr residues) (EC 2.7.12.*);   inhibitors of dual-specificity kinases (those acting on Ser/Thr and Tyr residues) (EC 2.7.12.*)



show annotations for term's descendants           Sort by:
 
PD 0325901 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adam19 ADAM metallopeptidase domain 19 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of ADAM19 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ADAM19 mRNA
CTD PMID:25119042 NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
JBrowse link
G Adamts6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ADAMTS6 mRNA CTD PMID:25119042 NCBI chr 2:35,421,483...35,633,305
Ensembl chr 2:35,421,510...35,633,298
JBrowse link
G Akap12 A-kinase anchoring protein 12 decreases expression ISO mirdametinib results in decreased expression of AKAP12 mRNA CTD PMID:25119042 NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation
ISO [mirdametinib co-treated with MK 2206] results in increased phosphorylation of AKT1 protein; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of AKT1 protein; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of AKT1 protein]; romidepsin inhibits the reaction [[mirdametinib co-treated with MK 2206] results in increased phosphorylation of AKT1 protein]
mirdametinib results in increased phosphorylation of AKT1 protein
CTD PMID:22415236 PMID:25798061 PMID:27634878 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Alb albumin decreases expression EXP mirdametinib results in decreased expression of ALB protein CTD PMID:21976371 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Ank3 ankyrin 3 multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ANK3 mRNA CTD PMID:25119042 NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
JBrowse link
G Ano1 anoctamin 1 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of ANO1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ANO1 mRNA
CTD PMID:25119042 NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
JBrowse link
G Anpep alanyl aminopeptidase, membrane decreases expression ISO mirdametinib results in decreased expression of ANPEP mRNA CTD PMID:25119042 NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
JBrowse link
G Arhgap24 Rho GTPase activating protein 24 multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ARHGAP24 mRNA CTD PMID:25119042 NCBI chr14:6,800,631...7,184,001
Ensembl chr14:6,800,631...7,183,823
JBrowse link
G Arl4c ADP ribosylation factor like GTPase 4C decreases expression ISO mirdametinib results in decreased expression of ARL4C mRNA CTD PMID:25119042 NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513
JBrowse link
G Bak1 BCL2-antagonist/killer 1 increases expression
multiple interactions
ISO mirdametinib results in increased expression of BAK1 protein
[mirdametinib co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with mirdametinib] results in increased expression of BAK1 protein
CTD PMID:27634878 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [mirdametinib co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with mirdametinib] results in increased expression of BCL2L11 protein; KRAS protein affects the reaction [mirdametinib results in increased expression of BCL2L11 protein]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]]; NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein] CTD PMID:24576621 PMID:27634878 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [mirdametinib co-treated with MK 2206] results in increased expression of BID mRNA; [mirdametinib co-treated with MK 2206] results in increased expression of BID protein modified form CTD PMID:28691888 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of BIRC3 mRNA CTD PMID:25119042 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CCL20 mRNA
mirdametinib results in decreased expression of CCL20 mRNA
CTD PMID:25119042 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCND1 protein] CTD PMID:25104499 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd3 cyclin D3 multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCND3 protein] CTD PMID:25104499 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCNE1 protein] CTD PMID:25104499 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CXCL1 mRNA
mirdametinib results in decreased expression of CXCL1 mRNA
CTD PMID:25119042 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CXCL1 mRNA
mirdametinib results in decreased expression of CXCL1 mRNA
CTD PMID:25119042 NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
JBrowse link
G Cyb5r2 cytochrome b5 reductase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of CYB5R2 mRNA
mirdametinib results in decreased expression of CYB5R2 mRNA
CTD PMID:25119042 NCBI chr 1:161,655,862...161,664,359
Ensembl chr 1:161,655,864...161,664,097
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 decreases expression
increases expression
EXP mirdametinib results in decreased expression of CYP24A1 mRNA
mirdametinib results in increased expression of CYP24A1 mRNA
CTD PMID:21976371 PMID:23872713 NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
JBrowse link
G Cyp27b1 cytochrome P450, family 27, subfamily b, polypeptide 1 increases expression EXP mirdametinib results in increased expression of CYP27B1 mRNA CTD PMID:21976371 NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression ISO mirdametinib results in increased expression of CYP3A4 mRNA CTD PMID:24819614 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases expression ISO mirdametinib results in increased expression of CYP3A5 mRNA CTD PMID:24819614 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
JBrowse link
G Dcbld2 discoidin, CUB and LCCL domain containing 2 decreases expression ISO mirdametinib results in decreased expression of DCBLD2 mRNA CTD PMID:25119042 NCBI chr11:42,125,787...42,179,927
Ensembl chr11:42,125,787...42,179,697
JBrowse link
G Dnmbp dynamin binding protein decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of DNMBP mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DNMBP mRNA
CTD PMID:25119042 NCBI chr 1:242,736,189...242,829,498
Ensembl chr 1:242,736,189...242,802,604
JBrowse link
G Dock4 dedicator of cytokinesis 4 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DOCK4 mRNA
mirdametinib results in decreased expression of DOCK4 mRNA
CTD PMID:25119042 NCBI chr 6:57,512,929...57,902,597
Ensembl chr 6:57,512,908...57,901,855
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of DUSP4 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DUSP4 mRNA
CTD PMID:25119042 NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
JBrowse link
G Dusp6 dual specificity phosphatase 6 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DUSP6 mRNA
mirdametinib results in decreased expression of DUSP6 mRNA
CTD PMID:25119042 NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
JBrowse link
G Efna5 ephrin A5 multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of EFNA5 mRNA CTD PMID:25119042 NCBI chr 9:102,316,753...102,595,480
Ensembl chr 9:102,320,295...102,597,413
JBrowse link
G Egr1 early growth response 1 decreases expression
multiple interactions
EXP
ISO
mirdametinib results in decreased expression of EGR1 mRNA
mirdametinib inhibits the reaction [camostat results in increased expression of EGR1 mRNA]
CTD PMID:21976371 PMID:25104499 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [Ku 0063794 co-treated with mirdametinib] results in decreased phosphorylation of EIF4EBP1 protein; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:22415236 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Emp1 epithelial membrane protein 1 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of EMP1 mRNA
mirdametinib results in decreased expression of EMP1 mRNA
CTD PMID:25119042 NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression
ISO mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]; mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 protein]
mirdametinib results in decreased expression of ERCC1 mRNA
CTD PMID:21996734 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases expression ISO mirdametinib results in increased expression of ERCC4 mRNA CTD PMID:21996734 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
JBrowse link
G Esm1 endothelial cell-specific molecule 1 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ESM1 mRNA
mirdametinib results in decreased expression of ESM1 mRNA
CTD PMID:25119042 NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETS1 mRNA CTD PMID:25119042 NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
JBrowse link
G Etv1 ETS variant transcription factor 1 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV1 mRNA
mirdametinib results in decreased expression of ETV1 mRNA
CTD PMID:25119042 NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
JBrowse link
G Etv4 ETS variant transcription factor 4 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV4 mRNA
mirdametinib results in decreased expression of ETV4 mRNA
CTD PMID:25119042 NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974
JBrowse link
G Etv5 ETS variant transcription factor 5 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV5 mRNA
mirdametinib results in decreased expression of ETV5 mRNA
CTD PMID:25119042 NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO mirdametinib inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]] CTD PMID:26670611 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fgf23 fibroblast growth factor 23 multiple interactions EXP mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]; mirdametinib results in increased expression of and results in increased secretion of FGF23 protein CTD PMID:23872713 NCBI chr 4:159,914,393...159,922,073
Ensembl chr 4:159,914,272...159,923,821
JBrowse link
G Fmnl2 formin-like 2 decreases expression ISO mirdametinib results in decreased expression of FMNL2 mRNA CTD PMID:25119042 NCBI chr 3:37,348,791...37,624,746
Ensembl chr 3:37,348,574...37,624,754
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression
multiple interactions
EXP
ISO
mirdametinib results in decreased expression of FOS mRNA
mirdametinib inhibits the reaction [camostat results in increased expression of FOS mRNA]
CTD PMID:21976371 PMID:25104499 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of FOSL1 protein
[mirdametinib co-treated with silmitasertib] results in decreased expression of FOSL1 protein
CTD PMID:25798061 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
JBrowse link
G Foxg1 forkhead box G1 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of FOXG1 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of FOXG1 mRNA
CTD PMID:25119042 NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607
JBrowse link
G Foxo3 forkhead box O3 increases expression
multiple interactions
ISO mirdametinib results in increased expression of FOXO3 protein
mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; mirdametinib promotes the reaction [Luteolin results in increased expression of FOXO3 protein]
CTD PMID:32268164 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
JBrowse link
G Glrx glutaredoxin multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of GLRX mRNA
mirdametinib results in decreased expression of GLRX mRNA
CTD PMID:25119042 NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
JBrowse link
G Gypc glycophorin C (Gerbich blood group) multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of GYPC mRNA
mirdametinib results in decreased expression of GYPC mRNA
CTD PMID:25119042 NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204
JBrowse link
G Has2 hyaluronan synthase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HAS2 mRNA
mirdametinib results in decreased expression of HAS2 mRNA
CTD PMID:25119042 NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
JBrowse link
G Hdac9 histone deacetylase 9 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of HDAC9 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HDAC9 mRNA
CTD PMID:25119042 NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HSD17B2 mRNA
mirdametinib results in decreased expression of HSD17B2 mRNA
CTD PMID:25119042 NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
JBrowse link
G Hsf1 heat shock transcription factor 1 decreases activity ISO mirdametinib results in decreased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
JBrowse link
G Htr7 5-hydroxytryptamine receptor 7 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of HTR7 mRNA
mirdametinib results in decreased expression of HTR7 mRNA
CTD PMID:25119042 NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
JBrowse link
G Ifng interferon gamma multiple interactions ISO mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL15 protein results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL2 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of IGFBP3 mRNA CTD PMID:25119042 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
JBrowse link
G Il15 interleukin 15 multiple interactions ISO mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL15 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
JBrowse link
G Il18 interleukin 18 multiple interactions ISO mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of IL1B mRNA
mirdametinib results in decreased expression of IL1B mRNA
CTD PMID:25119042 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of IL1RAPL1 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of IL1RAPL1 mRNA
CTD PMID:25119042 NCBI chr  X:51,371,969...52,876,726
Ensembl chr  X:51,378,215...52,876,772
JBrowse link
G Il2 interleukin 2 multiple interactions ISO mirdametinib inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Inhba inhibin subunit beta A multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of INHBA mRNA CTD PMID:25119042 NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
JBrowse link
G Itga2 integrin subunit alpha 2 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ITGA2 mRNA
mirdametinib results in decreased expression of ITGA2 mRNA
CTD PMID:25119042 NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
JBrowse link
G Itgbl1 integrin subunit beta like 1 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ITGBL1 mRNA
mirdametinib results in decreased expression of ITGBL1 mRNA
CTD PMID:25119042 NCBI chr15:100,780,184...101,041,734
Ensembl chr15:100,780,184...101,041,733
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression EXP mirdametinib results in decreased expression of JUN mRNA CTD PMID:21976371 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Kif24 kinesin family member 24 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of KIF24 mRNA
mirdametinib results in decreased expression of KIF24 mRNA
CTD PMID:25119042 NCBI chr 5:56,561,019...56,628,040
Ensembl chr 5:56,561,154...56,628,025
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of KIT mRNA
mirdametinib results in decreased expression of KIT mRNA
CTD PMID:25119042 NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
JBrowse link
G Klrk1 killer cell lectin like receptor K1 multiple interactions ISO mirdametinib inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein] CTD PMID:27563819 NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459
JBrowse link
G Kras KRAS proto-oncogene, GTPase multiple interactions ISO KRAS protein affects the reaction [mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased expression of MCL1 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [mirdametinib results in increased expression of BCL2L11 protein]; KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [mirdametinib results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]]; KRAS protein affects the susceptibility to [[mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; KRAS protein affects the susceptibility to [mirdametinib co-treated with NVP-BKM120]
[mirdametinib affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]
CTD PMID:24576621 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G LOC100362814 hypothetical protein LOC100362814 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of KIAA1549L mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of KIAA1549L mRNA
CTD PMID:25119042 NCBI chr 3:90,506,559...90,782,427
Ensembl chr 3:90,510,942...90,781,894
JBrowse link
G Lpl lipoprotein lipase multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of LPL mRNA CTD PMID:25119042 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Lpxn leupaxin multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of LPXN mRNA
mirdametinib results in decreased expression of LPXN mRNA
CTD PMID:25119042 NCBI chr 1:209,928,297...209,963,085
Ensembl chr 1:209,929,202...209,963,084
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO mirdametinib inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:32268164 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO
EXP
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of MAPK1 protein; [MK 2206 co-treated with mirdametinib] results in decreased phosphorylation of MAPK1 protein; dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [mirdametinib results in increased phosphorylation of MAPK1 protein]]; mirdametinib inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [Axitinib results in decreased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK1 protein]
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]
mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]
CTD PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO
EXP
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of MAPK3 protein; [MK 2206 co-treated with mirdametinib] results in decreased phosphorylation of MAPK3 protein; dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [Axitinib results in decreased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK3 protein]
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein]
mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]
CTD PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
decreases expression
increases expression
ISO [mirdametinib co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with mirdametinib] results in increased expression of MCL1 protein; KRAS protein affects the reaction [mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased expression of MCL1 protein]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]]; mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]; NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]
mirdametinib results in increased expression of MCL1 protein
CTD PMID:24576621 PMID:27634878 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Mgll monoglyceride lipase multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of MGLL mRNA
mirdametinib results in decreased expression of MGLL mRNA
CTD PMID:25119042 NCBI chr 4:121,192,187...121,294,187
Ensembl chr 4:121,192,195...121,294,179
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [mirdametinib affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]; mirdametinib inhibits the reaction [camostat results in increased expression of MKI67 protein] CTD PMID:24576621 PMID:25104499 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Mmd monocyte to macrophage differentiation-associated multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMD mRNA
mirdametinib results in decreased expression of MMD mRNA
CTD PMID:25119042 NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMP1 mRNA
mirdametinib results in decreased expression of MMP1 mRNA
CTD PMID:25119042 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Mmp10 matrix metallopeptidase 10 multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMP10 mRNA CTD PMID:25119042 NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:29384525 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression
ISO (+)-JQ1 compound promotes the reaction [mirdametinib results in decreased expression of MYC protein]; mirdametinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein] CTD PMID:26284497 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nav3 neuron navigator 3 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of NAV3 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of NAV3 mRNA
CTD PMID:25119042 NCBI chr 7:45,052,206...45,840,471
Ensembl chr 7:45,054,296...45,840,698
JBrowse link
G Ncr3 natural cytotoxicity triggering receptor 3 multiple interactions ISO mirdametinib inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of NCR3 protein] CTD PMID:27563819 NCBI chr20:3,637,242...3,643,748
Ensembl chr20:3,638,240...3,643,799
JBrowse link
G Nf1 neurofibromin 1 multiple interactions ISO NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib]] CTD PMID:25119042 NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
JBrowse link
G Nme5 NME/NM23 family member 5 multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of NME5 mRNA CTD PMID:25119042 NCBI chr18:26,163,558...26,180,742
Ensembl chr18:26,163,555...26,180,794
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 decreases expression ISO mirdametinib results in decreased expression of NR0B2 mRNA CTD PMID:24819614 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
JBrowse link
G Nrcam neuronal cell adhesion molecule decreases expression ISO mirdametinib results in decreased expression of NRCAM mRNA CTD PMID:25119042 NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992
JBrowse link
G Nrp1 neuropilin 1 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of NRP1 mRNA
mirdametinib results in decreased expression of NRP1 mRNA
CTD PMID:25119042 NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
JBrowse link
G Ntm neurotrimin multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of NTM mRNA
mirdametinib results in decreased expression of NTM mRNA
CTD PMID:25119042 NCBI chr 8:27,376,582...28,366,604
Ensembl chr 8:27,377,773...28,366,595
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [mirdametinib co-treated with MK 2206] results in increased cleavage of PARP1 protein; [mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein; KRAS protein affects the susceptibility to [[mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; mirdametinib promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [[mirdametinib co-treated with MK 2206] results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [mirdametinib results in increased cleavage of PARP1 protein] CTD PMID:24576621 PMID:27634878 PMID:32268164 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of PCNA protein] CTD PMID:25104499 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pdcd1lg2 programmed cell death 1 ligand 2 multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PDCD1LG2 mRNA CTD PMID:25119042 NCBI chr 1:227,158,941...227,223,938
Ensembl chr 1:227,158,941...227,223,938
JBrowse link
G Peg3 paternally expressed 3 decreases expression ISO mirdametinib results in decreased expression of PEG3 mRNA CTD PMID:25119042 NCBI chr 1:67,097,874...67,124,692
Ensembl chr 1:67,097,904...67,124,671
JBrowse link
G Plau plasminogen activator, urokinase multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PLAU mRNA
mirdametinib results in decreased expression of PLAU mRNA
CTD PMID:25119042 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
JBrowse link
G Plaur plasminogen activator, urokinase receptor multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PLAUR mRNA
mirdametinib results in decreased expression of PLAUR mRNA
CTD PMID:25119042 NCBI chr 1:80,053,441...80,068,384
Ensembl chr 1:80,050,324...80,068,595
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO mirdametinib inhibits the reaction [Protein Kinase Inhibitors results in increased phosphorylation of and results in decreased activity of PPARG protein] CTD PMID:26670611 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Prdm1 PR/SET domain 1 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of PRDM1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PRDM1 mRNA
CTD PMID:25119042 NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
JBrowse link
G Prrx1 paired related homeobox 1 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PRRX1 mRNA
mirdametinib results in decreased expression of PRRX1 mRNA
CTD PMID:25119042 NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866
JBrowse link
G Ptx3 pentraxin 3 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PTX3 mRNA
mirdametinib results in decreased expression of PTX3 mRNA
CTD PMID:25119042 NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
JBrowse link
G Rac1 Rac family small GTPase 1 affects response to substance ISO RAC1 protein alternative form affects the susceptibility to mirdametinib CTD PMID:23033341 NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
JBrowse link
G Reln reelin decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of RELN mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of RELN mRNA
CTD PMID:25119042 NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation
ISO 2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one promotes the reaction [mirdametinib results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [NVP-BKM120 results in decreased phosphorylation of RPS6 protein] CTD PMID:22415236 PMID:24011934 PMID:24576621 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Scg5 secretogranin V multiple interactions ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of SCG5 mRNA CTD PMID:25119042 NCBI chr 3:100,544,101...100,588,558
Ensembl chr 3:100,544,099...100,588,463
JBrowse link
G Sema3a semaphorin 3A multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SEMA3A mRNA
mirdametinib results in decreased expression of SEMA3A mRNA
CTD PMID:25119042 NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432
JBrowse link
G Siglec15 sialic acid binding Ig-like lectin 15 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of SIGLEC15 mRNA
mirdametinib results in decreased expression of SIGLEC15 mRNA
CTD PMID:25119042 NCBI chr18:71,507,773...71,521,722
Ensembl chr18:71,505,399...71,521,881
JBrowse link
G Slc6a15 solute carrier family 6 member 15 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SLC6A15 mRNA
mirdametinib results in decreased expression of SLC6A15 mRNA
CTD PMID:25119042 NCBI chr 7:38,553,055...38,607,239
Ensembl chr 7:38,553,196...38,607,239
JBrowse link
G Slit2 slit guidance ligand 2 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SLIT2 mRNA
mirdametinib results in decreased expression of SLIT2 mRNA
CTD PMID:25119042 NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression ISO mirdametinib results in decreased expression of SOX9 mRNA CTD PMID:25119042 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SPP1 mRNA CTD PMID:25119042 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Spry2 sprouty RTK signaling antagonist 2 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SPRY2 mRNA
mirdametinib results in decreased expression of SPRY2 mRNA
CTD PMID:25119042 NCBI chr15:82,692,312...82,697,408
Ensembl chr15:82,692,143...82,698,009
JBrowse link
G St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ST3GAL6 mRNA
mirdametinib results in decreased expression of ST3GAL6 mRNA
CTD PMID:25119042 NCBI chr11:42,061,282...42,121,801
Ensembl chr11:42,077,621...42,121,776
JBrowse link
G Stc1 stanniocalcin 1 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of STC1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of STC1 mRNA
CTD PMID:25119042 NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264
JBrowse link
G Stx1a syntaxin 1A multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of STX1A mRNA
mirdametinib results in decreased expression of STX1A mRNA
CTD PMID:25119042 NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930
JBrowse link
G Suz12 SUZ12 polycomb repressive complex 2 subunit multiple interactions ISO NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib]]; SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib] CTD PMID:25119042 NCBI chr10:64,967,035...65,012,916
Ensembl chr10:64,966,967...65,012,738
JBrowse link
G Syngap1 synaptic Ras GTPase activating protein 1 affects response to substance ISO SYNGAP1 protein affects the susceptibility to mirdametinib CTD PMID:29940508 NCBI chr20:5,026,366...5,056,659
Ensembl chr20:5,026,364...5,056,672
JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TBX3 mRNA
mirdametinib results in decreased expression of TBX3 mRNA
CTD PMID:25119042 NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TFPI mRNA
mirdametinib results in decreased expression of TFPI mRNA
CTD PMID:25119042 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
JBrowse link
G Tgm2 transglutaminase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TGM2 mRNA
mirdametinib results in decreased expression of TGM2 mRNA
CTD PMID:25119042 NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
JBrowse link
G Tlr4 toll-like receptor 4 decreases expression
multiple interactions
ISO mirdametinib results in decreased expression of TLR4 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TLR4 mRNA
CTD PMID:25119042 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tmem156 transmembrane protein 156 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TMEM156 mRNA
mirdametinib results in decreased expression of TMEM156 mRNA
CTD PMID:25119042 NCBI chr14:43,221,464...43,252,453
Ensembl chr14:43,223,381...43,252,449
JBrowse link
G Tnfsf15 TNF superfamily member 15 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TNFSF15 mRNA
mirdametinib results in decreased expression of TNFSF15 mRNA
CTD PMID:25119042 NCBI chr 5:77,140,099...77,156,142
Ensembl chr 5:77,139,878...77,156,228
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [mirdametinib co-treated with MK 2206] results in increased expression of and results in increased phosphorylation of TRP53 protein CTD PMID:28691888 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Trib2 tribbles pseudokinase 2 multiple interactions
decreases expression
ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TRIB2 mRNA
mirdametinib results in decreased expression of TRIB2 mRNA
CTD PMID:25119042 NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions ISO mirdametinib inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]] CTD PMID:26670611 NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
JBrowse link
G Ugt8 UDP glycosyltransferase 8 multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of UGT8 mRNA CTD PMID:25119042 NCBI chr 2:214,264,483...214,332,769
Ensembl chr 2:214,264,483...214,332,660
JBrowse link
G Vegfc vascular endothelial growth factor C multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of VEGFC mRNA
mirdametinib results in decreased expression of VEGFC mRNA
CTD PMID:25119042 NCBI chr16:37,712,408...37,827,657
Ensembl chr16:37,712,262...37,827,848
JBrowse link
G Zeb1 zinc finger E-box binding homeobox 1 multiple interactions ISO [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ZEB1 mRNA CTD PMID:25119042 NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
JBrowse link
SL-327 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions
increases expression
ISO SL 327 promotes the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]
SL 327 results in increased expression of AHR protein
CTD PMID:15572374 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Bdnf brain-derived neurotrophic factor increases response to substance
multiple interactions
ISO BDNF gene mutant form results in increased susceptibility to SL 327
SL 327 inhibits the reaction [Dronabinol results in increased expression of BDNF mRNA]
CTD PMID:12657697 PMID:16945347 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression
decreases secretion
EXP SL 327 results in decreased expression of CCL2 mRNA
SL 327 results in decreased secretion of CCL2 protein
CTD PMID:20050970 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of CREB1 protein] CTD PMID:16339038 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Egr1 early growth response 1 multiple interactions ISO SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 protein]; SL 327 inhibits the reaction [Dronabinol results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Dronabinol results in increased expression of EGR1 protein] CTD PMID:11553284 PMID:12657697 PMID:19931294 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions ISO SL 327 inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of ELK1 protein]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] CTD PMID:11553284 PMID:12871586 NCBI chr  X:1,138,826...1,155,713
Ensembl chr  X:1,139,756...1,155,713
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO
EXP
SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased expression of FOS protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased expression of FOS protein]; SL 327 inhibits the reaction [Cocaine results in increased activity of FOS protein]; SL 327 inhibits the reaction [Cocaine results in increased expression of FOS mRNA]; SL 327 inhibits the reaction [Cocaine results in increased expression of FOS protein]; SL 327 inhibits the reaction [Dronabinol results in increased expression of FOS protein]
SL 327 inhibits the reaction [Amphetamine results in increased expression of FOS mRNA]; SL 327 inhibits the reaction [Naloxone results in increased expression of FOS protein]
CTD PMID:11553284 PMID:12657697 PMID:15056714 PMID:15447667 PMID:16263220 More... NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Fosb FosB proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased expression of FOSB protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased expression of FOSB protein]; SL 327 inhibits the reaction [Cocaine results in increased expression of FOSB protein alternative form] CTD PMID:15056714 PMID:16263220 NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
JBrowse link
G Fosl2 FOS like 2, AP-1 transcription factor subunit multiple interactions ISO SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased expression of FOSL2 protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased expression of FOSL2 protein] CTD PMID:15056714 NCBI chr 6:24,297,898...24,319,157
Ensembl chr 6:24,300,956...24,320,034
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]] CTD PMID:25550330 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]] CTD PMID:25550330 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions ISO SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of GRIA1 protein] CTD PMID:16473939 NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
JBrowse link
G Il1b interleukin 1 beta decreases expression EXP SL 327 results in decreased expression of IL1B CTD PMID:20050970 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO SL 327 inhibits the reaction [Cocaine results in increased expression of JUNB protein] CTD PMID:16263220 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
JBrowse link
G Kl Klotho multiple interactions ISO SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]] CTD PMID:25550330 NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO
EXP
SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased expression of FOS protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased expression of FOSB protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased expression of FOSL2 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]]; SL 327 inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK1 protein]
SL 327 results in decreased phosphorylation of MAPK1 protein
SL 327 inhibits the reaction [HU 211 results in increased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [Isoproterenol results in increased phosphorylation of MAPK1 protein]; SL 327 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
CTD PMID:12657697 PMID:12871586 PMID:15056714 PMID:16473939 PMID:17596448 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO
EXP
SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased expression of FOS protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased expression of FOSB protein]; SL 327 inhibits the reaction [[Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased expression of FOSL2 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]]; SL 327 inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK3 protein]
SL 327 inhibits the reaction [HU 211 results in increased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Isoproterenol results in increased phosphorylation of MAPK3 protein]; SL 327 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
SL 327 results in decreased phosphorylation of MAPK3 protein
CTD PMID:12657697 PMID:12871586 PMID:15056714 PMID:16473939 PMID:17596448 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]] CTD PMID:25550330 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Pdyn prodynorphin multiple interactions EXP SL 327 inhibits the reaction [Dextroamphetamine results in increased expression of PDYN mRNA] CTD PMID:16459022 NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
JBrowse link
G Penk proenkephalin multiple interactions EXP SL 327 inhibits the reaction [Dextroamphetamine results in increased expression of PENK mRNA] CTD PMID:16459022 NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
JBrowse link
G Ptpn5 protein tyrosine phosphatase, non-receptor type 5 multiple interactions EXP SL 327 inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] CTD PMID:17623046 NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882
JBrowse link
G Rnd3 Rho family GTPase 3 multiple interactions ISO SL 327 inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of RND3 mRNA] CTD PMID:17196187 NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327
JBrowse link
G Rps6ka5 ribosomal protein S6 kinase A5 multiple interactions ISO SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein]; SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] CTD PMID:16339038 PMID:17596448 NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20050
    role 20001
      biological role 20000
        biochemical role 19624
          enzyme inhibitor 18568
            EC 2.* (transferase) inhibitor 14001
              EC 2.7.* (P-containing group transferase) inhibitor 13634
                EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor 148
                  4-(6-ethoxypyrazolo[1,5-b]pyridazin-3-yl)-N-(3-methoxyphenyl)pyrimidin-2-amine 0
                  BI00036838 0
                  EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor + 148
                  N-(2-[(2-aminoethyl)(methyl)amino]-5-\{[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino\}phenyl)acetamide 0
                  SGC-CLK-1 0
paths to the root